Clinical Trial Update: Rifamycin SV-MMX® 400 mg b.i.d. vs. Rifamycin SV-MMX® 600 mg t.i.d. vs. Placebo in Acute Uncomplicated Diverticulitis [Phase 2]

View source ↗

Summary

A Phase 2 study comparing Rifamycin SV-MMX at 400 mg twice daily or 600 mg three times daily to placebo in patients with acute uncomplicated diverticulitis. The…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diverticulitis

Drugs mentioned

• Rifamycin SV-MMX 400 mg b.i.d. (rifamycin SV-MMX)
• Rifamycin SV-MMX 600 mg t.i.d. (rifamycin SV-MMX)

Snippet

Sponsor: Dr. Falk Pharma GmbH | Conditions: Uncomplicated Diverticulitis | Phase 2 | Status: COMPLETED